Munro Partners Eli Lilly & CO Transaction History

Munro Partners

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 14, 2025	SELL	$625.65 - $812.69 $79.4 Million - $103 Million	-126,836 Closed	0 $0
Q2 2025 Oct 14, 2025	BUY	$713.71 - $898.95 $31 Million - $39.1 Million	43,470 Added 52.14%	126,836 $98.9 Billion
Q2 2025 Aug 26, 2025	BUY	$713.71 - $898.95 $90.5 Million - $114 Million	126,836 New	126,836 $98.9 Billion
Q1 2025 Oct 10, 2025	SELL	$725.72 - $929.72 $24.3 Million - $31.1 Million	-33,450 Reduced 26.37%	93,386 $77.1 Billion
Q4 2024 Oct 14, 2025	SELL	$727.2 - $932.06 $31.6 Million - $40.5 Million	-43,470 Reduced 34.27%	83,366 $64.4 Billion
Q3 2024 Oct 20, 2025	SELL	$772.14 - $960.02 $4.21 Million - $5.23 Million	-5,450 Reduced 6.08%	84,116 $74.5 Billion
Q2 2024 Oct 20, 2025	SELL	$724.87 - $909.04 $855,346 - $1.07 Million	-1,180 Reduced 1.3%	89,566 $81.1 Billion
Q1 2024 Oct 20, 2025	BUY	$592.2 - $792.28 $53.7 Million - $71.9 Million	90,746 New	90,746 $70.6 Billion

4,445

781M

16.5M

12.2M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $760B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Munro Partners, based on Form 13F filings with the SEC.

Stay updated on Munro Partners with notifications on news.